Literature DB >> 20505010

Formation of virus-like particles from human cell lines exclusively expressing influenza neuraminidase.

Jimmy C C Lai1, Wallace W L Chan, François Kien, John M Nicholls, J S Malik Peiris, Jean-Michel Garcia.   

Abstract

The minimal virus requirements for the generation of influenza virus-like particle (VLP) assembly and budding were reassessed. Using neuraminidase (NA) from the H5N1 and H1N1 subtypes, it was found that the expression of NA alone was sufficient to generate and release VLPs. Biochemical and functional characterization of the NA-containing VLPs demonstrated that they were morphologically similar to influenza virions. The NA oligomerization was comparable to that of the live virus, and the enzymic activity, whilst not required for the release of NA-VLPs, was preserved. Together, these findings indicate that NA plays a key role in virus budding and morphogenesis, and demonstrate that NA-VLPs represent a useful tool in influenza research.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20505010     DOI: 10.1099/vir.0.019935-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  30 in total

1.  Budding capability of the influenza virus neuraminidase can be modulated by tetherin.

Authors:  Mark A Yondola; Fiona Fernandes; Alan Belicha-Villanueva; Melissa Uccelini; Qinshan Gao; Carol Carter; Peter Palese
Journal:  J Virol       Date:  2011-01-05       Impact factor: 5.103

2.  Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice.

Authors:  Judith D Easterbrook; Louis M Schwartzman; Jin Gao; John C Kash; David M Morens; Laura Couzens; Hongquan Wan; Maryna C Eichelberger; Jeffery K Taubenberger
Journal:  Virology       Date:  2012-06-22       Impact factor: 3.616

3.  A mutant influenza virus that uses an N1 neuraminidase as the receptor-binding protein.

Authors:  Kathryn A Hooper; Jesse D Bloom
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

4.  Modulation of an ectodomain motif in the influenza A virus neuraminidase alters tetherin sensitivity and results in virus attenuation in vivo.

Authors:  Victor H Leyva-Grado; Rong Hai; Fiona Fernandes; Alan Belicha-Villanueva; Carol Carter; Mark A Yondola
Journal:  J Mol Biol       Date:  2013-12-29       Impact factor: 5.469

Review 5.  Protein-lipid interactions critical to replication of the influenza A virus.

Authors:  Petr Chlanda; Joshua Zimmerberg
Journal:  FEBS Lett       Date:  2016-03-30       Impact factor: 4.124

6.  F1Fo-ATPase, F-type proton-translocating ATPase, at the plasma membrane is critical for efficient influenza virus budding.

Authors:  Takeo Gorai; Hideo Goto; Takeshi Noda; Tokiko Watanabe; Hiroko Kozuka-Hata; Masaaki Oyama; Ryo Takano; Gabriele Neumann; Shinji Watanabe; Yoshihiro Kawaoka
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-05       Impact factor: 11.205

Review 7.  Influenza virus assembly and budding.

Authors:  Jeremy S Rossman; Robert A Lamb
Journal:  Virology       Date:  2011-01-14       Impact factor: 3.616

8.  Mutations in the membrane-proximal region of the influenza A virus M2 protein cytoplasmic tail have modest effects on virus replication.

Authors:  Shaun M Stewart; Andrew Pekosz
Journal:  J Virol       Date:  2011-09-14       Impact factor: 5.103

9.  Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines.

Authors:  Robert B Couch; Robert L Atmar; Wendy A Keitel; John M Quarles; Janet Wells; Nancy Arden; Diane Niño
Journal:  Vaccine       Date:  2012-10-26       Impact factor: 3.641

10.  Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase.

Authors:  Robert B Couch; Robert L Atmar; Luis M Franco; John M Quarles; Janet Wells; Nancy Arden; Diane Niño; John W Belmont
Journal:  J Infect Dis       Date:  2013-01-10       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.